Brain Tumor Vaccines

Justin Lee; Benjamin R Uy; Linda M Liau

doi:10.1016/j.nec.2021.01.003

Brain Tumor Vaccines

Neurosurg Clin N Am. 2021 Apr;32(2):225-234. doi: 10.1016/j.nec.2021.01.003.

Authors

Justin Lee¹, Benjamin R Uy¹, Linda M Liau²

Affiliations

¹ UCLA Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, 300 Stein Plaza Driveway Suite 420 Los Angeles, CA 90095, USA.
² UCLA Department of Neurosurgery, David Geffen School of Medicine at UCLA, University of California Los Angeles, 300 Stein Plaza Driveway Suite 420 Los Angeles, CA 90095, USA. Electronic address: LLIAU@mednet.ucla.edu.

PMID: 33781504
DOI: 10.1016/j.nec.2021.01.003

Abstract

Peptide and dendritic cell vaccines activate the immune system against tumor antigens to combat brain tumors. Vaccines stimulate a systemic immune response by inducing both antitumor T cells as well as humoral immunity through antibody production to cross the blood-brain barrier and combat brain tumors. Recent trials investigating vaccines against peptides (ie, epithelial growth factor receptor variant III, survivin, heat shock proteins, or personalized tumor antigens) and dendritic cells pulsed with known peptides, messenger RNA or unknown tumor lysate targets demonstrate the potential for therapeutic cancer vaccines to become an important therapy for brain tumor treatment.

Keywords: Brain tumor immunotherapy; Brain tumor vaccines; Dendritic cell vaccines; Peptide vaccines.

Publication types

Review

MeSH terms

Antigens, Neoplasm
Brain
Brain Neoplasms* / therapy
Cancer Vaccines* / therapeutic use
Dendritic Cells
Humans

Substances

Antigens, Neoplasm
Cancer Vaccines